CMS-121

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CMS-121 是一种喹诺酮衍生物，是一种口服活性乙酰辅酶 A 羧化酶 1 (ACC1) 抑制剂。

CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities.(In Vitro):CMS-121 can increase acetyl-CoA in cells. CMS-121 (1 μM; 4 hours; HT22 cells) treatment also increases the phosphorylation of ACC1 at serine 79.(In Vivo):CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS-121 (~20 mg/kg; p.o; daily; for 4 months; female SAMP8 mice) treatment decreases cognitive decline and metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice.

CMS-121 (1 μM; 4 hours; HT22 cells) treatment increases the phosphorylation of ACC1 at serine 79. CMS-121 can increase acetyl-CoA in cells. Western Blot Analysis Cell Line:HT22 cells Concentration:1 μM Incubation Time:4 hours Result: Increases the phosphorylation of ACC1 at serine 79.

CMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. Animal Model:Female SAMP8 mice (9 months old)Dosage:~20 mg/kg/day Administration:Oral administration; daily; for 4 months Result:Reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain.

CMS121

Metabolic Enzyme/Protease

ACC

CMV| Feline herpesvirus type-1(FHV-1)| HSV-1| Nucleoside Antimetabolite/Analog

——

——

1353224-53-9

321.376

C20H19NO3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (155.58 mM)

Oc1ccc(cc1O)-c1cc(OC2CCCC2)c2ccccc2n1

——

(-20℃)

With Ice Pack

≥ 2 years